RT @drshrinidhi2020: The mega live which you shoudl not miss!! 2yrs of myeloMATCH

Discussing all things MRD, AML and Myelomatch including APL with some brilliant colleagues and friends @EHA_Hematology in beautiful Stockholm.#EHA2026 @sanamloghavi @TapKadia @DrChrisHourigan

The mega live which you shoudl not miss!! 2yrs of myeloMATCH

A new #myeloMATCH clinical trial, #CCTG ALC10 has opened in Canada! Exploring a new treatment option for older adults with acute myeloid leukemia #AML who may not be able to tolerate intensive chemotherapy. buff.ly/ABTpHbj #Hematology #ClinicalTrials @BCCancer @SWOG

MyeloMATCH data highlight how NGS can streamline fusion detection in AML/MDS and support faster diagnostic profiling. Read more: bit.ly/4dQRrCF #AML #leusm Intended for healthcare professionals. Independently supported by Thermo Fisher Scientific. Funders are allowed no influence.

On the latest episode of the Bench to Bedside podcast, Dr. Tara Lin and Dr. Jesus Gonzalez Lugo share an update on #MyeloMATCH, a first-of-its-kind national clinical trial designed to bring precision medicine to patients with #AML. Tune in today: bit.ly/3Jet1Uu

NGS shows high concordance with cytogenetic assays in myeloMATCH, supporting a role in rapid fusion detection in AML/MDS. Learn more: bit.ly/4dQRrCF #AMLsm #leusm Intended for healthcare professionals. Independently supported by Thermo Fisher Scientific. Funders are allowed no influence.

From biopsy to biology in <72h-MyeloMATCH is basically ‘precision oncology on fast-forward’. At #DAVAWhistler, Dr. Eric Winer (@DanaFarber) presents rapid multi-omic profiling → smarter AML/MDS trial assignment at scale.

Precision oncology is no longer “next.” It’s becoming the operating system for cancer care. In late 2025, the FDA approved imlunestrant with a liquid-biopsy companion diagnostic for ESR1-mutated breast cancer [1]. Regulators have also now formalized how ctDNA/MRD can support drug development in curative-intent solid tumors [2]. And NCI’s next-gen precision trials ComboMATCH, MyeloMATCH, iMATCH are already underway [3]. 🧬 That shifts the bottleneck from discovery to execution: testing access, turnaround time, reimbursement, and trial matching. The competitive edge won’t come only from better drugs, but from better systems ⚕️📉 The real question for leaders: build genomic infrastructure now or watch outcomes and investment concentrate elsewhere. 🤔 Where is precision oncology still overhyped, and where are health systems still moving dangerously too slowly? [1] [fda.gov/drugs/resources-info…](fda.gov/drugs/resources-info…) ([U.S. Food and Drug Administration][1]) [2] [fda.gov/media/183874/downloa…](fda.gov/media/183874/downloa…) ([U.S. Food and Drug Administration][2]) [3] [cancer.gov/about-nci/organiz…](cancer.gov/about-nci/organiz…) ([Cancer.gov][3]) #PrecisionMedicine #Oncology #LiquidBiopsy #CancerCare #Biotech [1]: fda.gov/drugs/resources-info… "FDA approves imlunestrant for ER-positive, HER2-negative, ESR1-mutated ..." [2]: fda.gov/media/183874/downloa… "Guidance for Industry U.S. Food and Drug Administration" [3]: cancer.gov/about-nci/organiz… "NCI-MATCH NCI National Cancer Institute"

#myeloMATCH is a large @theNCI research study testing treatments for adults with #AML or #MDS. Patients join before starting treatment & may have #ClinicalTrial options at all treatment stages. @ALLIANCE_org @CDNCancerTrials @eaonc @SWOG 1-800-4-CANCER or bit.ly/3KHMtxE

Fred Hutch's @MinFang17 presenting work at #ASH25 showing chromosome genomic array testing (CGAT) improves diagnostic yield in patients with #AML and #MDS and has the potential for better risk stratification - a @theNCI myelomatch and @SWOG report. ashpublications.org/blood/ar…

Fred Hutch's Xiaoyu Qu presenting work at #ASH on improving karyotype success for myeloMATCH. Enhanced workflows boosted karyotype yield in AML samples, ensuring more patients receive accurate cytogenetic data for precision trial enrollment. ashpublications.org/blood/ar…

The @theNCI #MyeloMATCH precision medicine trial for #AML or #MDS has some initial results that are being presented in an oral presentation and 5 posters at the #ASH25 meeting this weekend! Find out more here > buff.ly/6HaGwyz @SWOG @eaonc @ALLIANCE_org #NCORP

The @theNCI myeloMATCH precision medicine trial portfolio in myeloid cancers is highlighted in numerous presentations at the upcoming #ASH25 meeting. Learn more: dctd.cancer.gov/about/news-e… @SWOG @eaonc @ALLIANCE_org @CDNCancerTrials #NCORP

Wrapped up a great (and 1st!) @eaonc Fall Meeting in Philly! 🌆 Great talks on innovative tx, trial design and 📈role of AI. Great mentorship for 🐣🕵️ 🌟Exciting things ahead in #MyeloMATCH #leusm 🎉 to @keruakous of @GACancerCenter leading EAA241, an important Ph II MM trial!

Analytical performance of the NCI-myeloMATCH assay – a rapid turnaround genomic profiling assay for myeloid disorders. From @AMPath member Dr. Cecilia Yeung and colleagues from @fredhutch and @theNCI. Full text: jmdjournal.org/article/S1525…